EU Grants EUR 6M to the Clinical Development of Athera Biotechnologies's Cardiovascular Disease Antibody Therapy
6/17/2013 9:04:51 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
STOCKHOLM, SWEDEN – June 17, 2013. Athera Biotechnologies AB today announced
that future development costs of its fully human antibody PC-mAb up until proof
-of-concept will be co-funded by the European Union’s Seventh Framework
Programme for Research (FP7) through a collaborative research grant. Karolinska
Development AB owns 65% of Athera Biotechnologies AB.
Help employers find you! Check out all the jobs and post your resume.
comments powered by